NorthWest Biotherapeutics Inc (NWBO)

[ATLnsider]

Thanks hyperopia, you may also want to read 1 of my other previous posts regarding DCVax-L along with poly-ICLC:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174435365

In this post, we can see that the original objective of the 2010 clinical trial, was to determine the best TLR agonist to add as a component in the DCVax-L formulation. Not as an adjuvant treatment, but as a DCVax formulation component. The poly-ICLC would be co-administered along with DCVax-L, at the same time. The poly-ICLC would send “the danger signal”, and would act as an in vivo maturation agent that would mature and hyperactivate the dendritic cell in situ:

https://classic.clinicaltrials.gov/ct2/show/NCT01204684

The main purpose of this study is to evaluate the most effective immunotherapy vaccine components in patients with malignant glioma.

The (sp) investigators previous phase I study (IRB #03-04-053) already confirmed that this vaccine procedure is safe in patients with malignant brain tumors, and with an indication of extended survival in several patients. However, the previous trial design did not allow us to test which formulation of the vaccine was the most effective. This phase II study will attempt to dissect out which components are most effective together

The first trial was a competition to decide which TLR agonist to add to the DCVax-L formulation, either TLR-3 (poly-ICLC) or TLR-7 (imiquimod / resiquimod), as a component in the DCVax-L formulation, to act as an in vivo maturation agent:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3568250/

In contrast, we administered the Toll-like receptor (TLR) agonists, imiquimod or poly ICLC, following intradermal injections of ATL-DC to induce DC maturation in vivo. We previously demonstrated in pre-clinical models that the utilization of TLR agonists could enhance the survival and trafficking of DC in situ and enhance the priming of tumor antigen-specific T lymphocytes 31. The findings from this current study suggest that the induction of patient-specific anti-tumor immunity using ATL-DC vaccination and in situ maturation with TLR agonists may represent a preferred formulation for DC-based therapies

The DCVax-L vaccine is administered intradermally, and the poly-ICLC is administered intramuscularly, as illustrated by Dr. Robert Prins in 2014: